The obesity rate in the U.S. dropped to 37% this year, representing a notable decrease after reaching a record high of 39.9% in 2022, according to data from Gallup .

The decline may be in part due to the explosion in the use of GLP-1 medications like Wegovy and Zepbound.

The share of adults reporting use of these medications for weight control has more than doubled in the past 18 months — from 5.8% in early 2024 to 12.4% in Gallup’s latest survey.

Women use the treatments at higher rates (15.2%) than men (9.7%), and both groups saw usage more than double over the past year.

The question is, will the downward trend in obesity rates last? The answer will come down to whether people using pharmaceutical intervention also implement the lifestyle changes needed to sustain their weight los

See Full Page